BPA Call 36E79720A0019-36C24921N0367
Award Date
3/8/21
Potential Completion Date
3/12/21
Potential Value
$284K
Federal Agency
Veterans Integrated Service Network 9
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
East Hanover, NJ 07936, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of Kymriah, a specialized cell therapy cancer treatment, to the Department of Veterans Affairs (VA) through a Blanket Purchase Agreement (BPA) under Novartis Pharmaceuticals Corporation's Federal Supply Schedule (FSS) contract for pharmaceuticals and drugs. The BPA, valued at $283,555.92, was issued by the VA's Veterans Integrated Service Network 9 and has a completion date of January 29, 2021. Novartis Pharmaceuticals Corporation, a foreign-owned,...
This federal contract award to Novartis Pharmaceuticals Corporation, doing business as NPS, is for the delivery of Kymriah, a specialized cell therapy cancer treatment, to the U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA). The contract is issued as a delivery order against Novartis' existing Federal Supply Schedule (FSS) 61-IB contract for pharmaceuticals and drugs, which has a potential value of $5.4 billion and runs through August 2025. The specific delivery...
This firm fixed-price delivery order was awarded by the Department of Veterans Affairs Veterans Health Administration to Novartis Pharmaceuticals Corporation, a foreign-owned, for-profit manufacturer, to provide the Kymriah chimeric antigen receptor T-cell therapy to the Nashville VA Medical Center. The order, valued at $283,526.57, was issued against Novartis' Federal Supply Schedule 61-IB contract for pharmaceuticals and drugs, which has a total potential value of $5.4 billion. Kymriah is a...
The Department of Veterans Affairs Veterans Health Administration awarded a delivery order to Novartis Pharmaceuticals Corp., doing business as NPS, for the specialized cancer medication KYMRIAH (TISAGENLECLEUCEL). The $283,526.57 firm fixed price order was placed against Novartis' Federal Supply Schedule 61-IB contract for pharmaceuticals and drugs, which has a total potential value of $5.4 billion and extends through August 2025. Novartis, a foreign-owned for-profit manufacturer, has...
The Department of Veterans Affairs Veterans Health Administration awarded a $283,567.92 delivery order to Novartis Pharmaceuticals Corporation (doing business as NPS), a foreign-owned for-profit manufacturer of pharmaceuticals and drugs. The order was placed against Novartis' Federal Supply Schedule 61-IB contract for pharmaceuticals and drugs, which has a total potential value of $5.4 billion and runs through August 2025. The delivery order was for Novartis' Kymriah, a chimeric antigen receptor...
The Department of Veterans Affairs (VA) awarded a $283,526.57 firm fixed price delivery order to Novartis Pharmaceuticals Corporation, a foreign-owned for-profit manufacturer, to provide the emergency cancer treatment Tisagenlecleucel under the VA's Federal Supply Schedule contract for pharmaceuticals and drugs. The delivery order was issued by the VA Veterans Health Administration's Veterans Integrated Service Network 9 and did not have a set-aside designation. Novartis holds a $5.4 billion...
The Department of Veterans Affairs Veterans Health Administration awarded a delivery order to Novartis Pharmaceuticals Corp., doing business as NPS, for the emergency procurement of the cancer medication Kymriah. The $283,526.57 firm fixed price order was placed against Novartis' Federal Supply Schedule 61-IB contract for pharmaceuticals and drugs, which extends through August 2025. Novartis is a foreign owned, for-profit manufacturer that has provided specialized cell therapy treatments to VA...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 9 awarded a $283,555.92 delivery order to Novartis Pharmaceuticals Corp., doing business as NPS, for KYMRIAH CAR T cell therapy under the Pharmaceuticals and Drugs Federal Supply Schedule contract. The delivery order, which has no set-aside designation, is for emergency KYMRIAH CAR T cell therapy and has a completion date of January 21, 2021. The contract pricing is firm fixed price. The place...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 9 awarded a $283,526.57 delivery order to Novartis Pharmaceuticals Corp. for the provision of CAR T cells (Kymriah injection, suspension) under the Pharmaceuticals and Drugs (FSS-61-IB) GSA Schedule. The delivery order was awarded on November 5, 2020 with a completion date of November 5, 2020. The pricing is firm fixed price and performance will take place in East Hanover, New Jersey. The...
This federal contract award is for the delivery of the radiopharmaceutical PLUVICTO to the Cleveland VA Medical Center (VAMC). The $598,124.52 firm fixed price delivery order was issued against Novartis Pharmaceuticals Corporation's Federal Supply Schedule (FSS) contract for pharmaceuticals and drugs (FSS-61-IB). Novartis, a foreign-owned for-profit manufacturer, has provided specialized cancer therapies like Kymriah to VA networks and facilities under previous orders and agreements. This...